MBX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MBX Biosciences Inc is not a strong buy for a beginner, long-term investor at this moment. While the company has potential catalysts in its pipeline and analysts have issued favorable ratings with high price targets, the stock's technical indicators are neutral, options sentiment is mixed, and the financial performance shows significant losses. Additionally, there are no recent positive news or influential trades that suggest immediate upside. Given the investor's preference for long-term investment and the absence of strong buy signals, holding off on investing in MBX for now is recommended.
The MACD is negative and contracting, RSI is neutral at 54.233, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 37.648, with resistance at 40.448 and support at 34.848. Overall, the technical indicators suggest a neutral trend.
Guggenheim raised its price target to $88, and Barclays initiated coverage with an Overweight rating and $66 price target.
Goldman Sachs issued a Sell rating with an $18 price target, citing concerns about the platform's validity beyond canvuparatide and the risk/benefit profile. The stock also has a high historical volatility of 101.32, and options data suggests low put volume, which could indicate limited downside protection.
In Q3 2025, MBX reported zero revenue and a net income loss of $21.62M, though this was an improvement of 19.16% YoY. EPS increased to -0.63, up 16.67% YoY. While losses are narrowing, the company remains unprofitable with no revenue growth.
Analysts are generally positive on MBX, with multiple Buy ratings and price targets ranging from $50 to $88. However, Goldman Sachs initiated coverage with a Sell rating and a much lower price target of $18, citing concerns about the company's platform and upcoming catalysts.
